ASLAN Pharmaceuticals Limited (ASLN)

NASDAQ: ASLN · IEX Real-Time Price · USD

0.448

-0.022 (-4.68%)

At close: Apr 25, 2024, 4:00 PM

0.440

-0.008 (-1.74%)

Pre-market: Apr 26, 2024, 8:30 AM EDT

ASLAN Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016
Revenue	12	0	0	0	3	0	0	11.55
Cost of Revenue	0	0	0	0	0.41	0	0	0.13
Gross Profit	12	0	0	0	2.59	0	0	11.42
Selling, General & Admin	13.24	9.88	11.83	7.17	8.51	10.51	8.76	6.96
Research & Development	42.5	38	22.02	9.31	16.59	31.83	30.38	13.17
Other Operating Expenses	0	0	0	0	23.07	0	0	0
Operating Expenses	55.74	47.88	33.85	16.48	48.17	42.35	39.14	20.12
Operating Income	-43.74	-47.88	-33.85	-16.48	-45.58	-42.35	-39.14	-8.7
Interest Expense / Income	4.33	3.68	1.86	1.25	0.9	0.49	0.42	0.52
Other Expense / Income	-3.98	-0.27	-4.12	-0.76	0.18	-0.67	0.34	-0.17
Pretax Income	-44.09	-51.28	-31.59	-16.97	-46.66	-42.17	-39.89	-9.05
Income Tax	0.13	0.1	0	0	0.41	0.01	0	0
Net Income	-44.22	-51.38	-31.59	-16.97	-47.07	-42.19	-39.89	-9.05
Shares Outstanding (Basic)	430	349	326	192	162	150	168	-
Shares Outstanding (Diluted)	-	349	326	192	162	150	-	-
Shares Change	23.32%	7.07%	69.43%	18.37%	8.45%	-10.67%	-	-
EPS (Basic)	-2.75	-3.75	-2.50	-2.00	-7.25	-7.00	-8.00	-2.25
EPS (Diluted)	-2.75	-3.75	-2.50	-2.00	-7.25	-7.00	-8.00	-2.25
Free Cash Flow	-43.33	-35.99	-34.04	-15.05	-25.51	-62.81	-34.78	-6.25
Free Cash Flow Per Share	-2.52	-2.58	-2.61	-1.96	-3.93	-10.49	-5.19	-
Gross Margin	100.00%	-	-	-	86.42%	-	-	98.92%
Operating Margin	-364.46%	-	-	-	-1519.30%	-	-	-75.34%
Profit Margin	-368.50%	-	-	-	-1568.85%	-	-	-78.37%
Free Cash Flow Margin	-361.09%	-	-	-	-850.21%	-	-	-54.16%
EBITDA	-39.41	-47.28	-29.45	-15.43	-45.31	-41.44	-39.27	-8.45
EBITDA Margin	-328.39%	-	-	-	-1510.35%	-	-	-73.17%
Depreciation & Amortization	0.35	0.33	0.28	0.3	0.45	0.24	0.21	0.08
EBIT	-39.76	-47.61	-29.73	-15.72	-45.76	-41.68	-39.48	-8.52
EBIT Margin	-331.29%	-	-	-	-1525.20%	-	-	-73.83%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).